More and more new oral small molecules are entering the dermatologic arena. A relevant advantage over biologics is their oral bioavailability.
Small molecule inhibitors are organic compounds with different chemical structures and molecular weights ranging from 500 to 900 Da. As Prof. Lone Skov (Herlev-Gentofte Hospital, Denmark) pointed out, they have a simple structure and are easy to produce; hence, they are much cheaper than biologics [1,2]. Small molecules can easily diffuse across cell membranes to reach intracellular sites. Once the inhibitor enters the cells, it affects various other molecules and reduces cellular levels of specific proteins . In comparison to larger molecules such as monoclonal antibodies, they have the advantage of possible oral administration and ease of combination with other treatments .
TYK2 inhibitor promising in psoriasis
Prof. Lars Iversen (Aarhus University Hospital, Denmark) pointed ou...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Biologics: biosimilars and lifestyle Next Article
Insights into pathogenesis of AD define novel therapeutic targets »